Introduction Tocomin Ò represents commercially available mixture of naturally occurring tocotrienols (T3s) and tocopherols extracted from palm oil/palm fruits that possess powerful antioxidant, anticancer, neuro/cardioprotective and cholesterol-lowering properties. Cellular autophagy represents a defense mechanism against oxidative stress and several anticancer compounds. Recently, we reported that T3s induce apoptosis and endoplasmic reticulum stress in breast cancer cells. Methodology We studied the effects of Tocomin Ò on MCF-7 and MDA-MB 231 breast cancer cells and nontumor MCF-10A cells. Results Tocomin Ò inhibited cell proliferation and induced apoptosis in both MCF-7 and MDA-MB 231 breast cancer cell lines without affecting the viability of MCF-10A cells. We also showed that Tocomin Ò negatively modulates phosphoinositide 3-kinase and mTOR pathways and induces cytoprotective autophagic response in triple negative MDA-MB 231 cells. Lastly, we demonstrate that autophagy inhibitor 3-methyladenine (3-MA) potentiated the apoptosis induced by Tocomin Ò in MDA-MB 231 cells.
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Introduction
Vitamin E is composed of tocopherols (Ts) and tocotrienols (T3s) that have been shown to possess anticancer properties. Tocomin Ò represents commercially available mixture of naturally occurring T3s (78 %) and Ts (22 %) extracted from palm oil/palm fruits. It also contains other phytonutrients such as plant squalene, phytosterols, coenzyme Q10 and mixed carotenoids extracted along with T3s from palm fruits. Palm oil is predominantly rich in T3s and has been demonstrated to possess more powerful antioxidant, anticancer, neuro/cardioprotective and cholesterollowering properties than Ts [1] [2] [3] . Both Ts and T3s exist as four isoforms each (a, b, c and d). The accumulation of T3s in the cells is much greater than Ts and might be one of the reasons of a more significant physiological effect of T3s than Ts [4] .
T3s have been shown to inhibit the growth of various cancer cells including breast cancer without affecting the growth of normal cells [5] [6] [7] [8] . T3s have been evaluated in vitro and in vivo as powerful cancer chemotherapeutic/ preventive agents, yet their exact mechanisms of action on cell death and other inhibitory pathways are unknown [7, [9] [10] [11] [12] . Various mechanisms including blocking oxidative stress or radiation-induced DNA damage [7, 13] , modulation of immune response [14, 15] , suppression of multiple oncogenic signaling molecules and pathways such as PI3K/ AKT/b-catenin, NF-jB, ERK and cyclin D1 [16] [17] [18] [19] [20] [21] and ceramide synthesis [22] have been suggested. Also, studies have shown that T3s inhibit cell migration and invasion by modulating matrix metalloproteinases and their inhibitors [23] as well as negatively modulate VEGF-dependent angiogenesis [24] . T3s exhibit cell inhibitory effects in breast cancer cell lines irrespective of their ER status, gene expression profiling in estrogen receptor (ER) positive, p53 wild-type MCF-7 and ER negative, p53 mutant MDA-MB 231 cells treated with tocotrienol-rich fraction (TRF) of palm oil suggested different mechanisms in the two cell lines [25] . Other mechanisms including activation of proapoptotic pathways including caspase-8 activation and mitochondrial dependency modulation of p53, Bax/Bcl2 [17, [26] [27] [28] , have been reported. Recent studies from our laboratory have suggested the role of ATF3 in the apoptosis induced by c-T3 [29] . Also, we demonstrated the modulation PERK and IRE1a-dependent endoplasmic reticulum stress (ER stress) and unfolded protein response (UPR)-related pathways in MCF-7 and MDA-MB 231 cells when treated with c-T3 [29] . ER stress activates UPR that can reestablish endoplasmic reticulum homeostasis through autophagy; however, persistent UPR can also lead to apoptosis. We demonstrated earlier that c-T3 activates PERK signaling, which has also been shown to induce autophagy as a protective response to cellular insults, such as hypoxia and nutrient deprivation [29] [30] [31] [32] . Similarly, IRE1a has also been implicated in autophagic response [31, 33, 34] . In the present study, we used commercially available Tocomin Ò as a source of naturally occurring dietary T3s and studied its effects on inducing autophagy and apoptosis. Further, we used 3-methyladenine (3-MA), a widely used autophagy inhibitor to study whether combined treatment of 3-MA with Tocomin Ò modulates apoptosis in breast cancer cells. 
Materials and methods

Cell
Cell viability and proliferation assay Effects of Tocomin
Ò on cell viability and proliferation were determined as described earlier [29] 
MDC staining
Monodansylcadaverine (MDC) staining was used as a marker of autophagic vacuoles and lysosomes using autophagy/cytotoxicity dual staining kit (Cayman Chemical Company, Ann Arbor, MI, USA). Autophagic vacuole staining intensity was measured using an excitation wavelength of 335 nm and an emission wavelength of 512 nm following the manufacturer's instructions.
Western blotting
Immunoblotting was performed essentially as described previously [29] . Each experiment was performed at least 2 times. Representative Western blots are shown.
Statistical analyses
Cell proliferation experiments were performed in 6 replicates. Student's T test was used to analyze treated versus untreated cells. Results were expressed as averages ± SD. P \ 0.05 was considered significant.
Results
Dietary T3s Tocomin
Ò inhibits the proliferation of human breast cancer cells
We compared the effects of Tocomin Ò on the viability of MCF-10A mammary epithelial cells, and MCF-7 and MDA-MB 231 breast cancer cells using WST-1 assay. As shown in Fig. 1 (Fig. 2) .
Tocomin
Ò induces autophagic response in MDA-MB 231 cells Autophagy provides certain advantage to tumor cells, and an autophagic response has been shown to be associated with almost all anticancer regimens as tumor cellintrinsic, resistance mechanism [35] [36] [37] [38] . Paradoxically, autophagy is also induced by dietary compounds with cancer chemopreventative properties, and an important role of autophagy has been suggested in chemoprevention of cancer [31, 34, 37] . Autophagic response also precedes an apoptotic response in certain cases of autophagic cell death. To obtain clues as to the mechanism by which Tocomin Ò induces apoptosis and whether, an autophagic response is a part of Tocomin Ò -induced cell signaling, we performed MDC fluorescent staining to measure autophagy in response to Tocomin Ò . MCF-7 and MDA-MB 231 cells were treated with Tocomin Ò ranging Fig. 1 Tocomin Ò inhibits the proliferation of MCF-7 and MDA-MB 231 breast cancer cells. Cells were seeded at a density of 3,000 cells/ well in a 96-well plate and treated with DMSO control or indicated concentrations of Tocomin Ò for 24 h. Cell proliferation was determined by WST-1 assay (Roche). A representative of three experiments performed in six replicates each is shown. P \ 0.05 (*) was considered significant Fig. 2 Tocomin Ò induces apoptosis in MCF-7 and MDA-MB 231 cells. Cells were treated with indicated concentrations of Tocomin from 10 to 100 lg/ml in a 96-well plate. Cells were incubated with the autofluorescent drug MDC, a specific autophagosome marker to detect autophagy. Figure 3a revealed that Tocomin Ò increased MDC fluorescence intensity only in MDA-MB 231, but not in MCF-7 cells, indicating that Tocomin Ò causes an increase in autophagy in MDA-MB 231 cells, but not in MCF-7 cells. Furthermore, we also confirmed the results by detecting the LC3b-II conversion by Western blotting. Both the cell lines were treated with indicated concentrations of Tocomin Ò from 10 to 80 lg/ml for 24 h followed by Western blotting with antibodies to the autophagic marker LC3b. As shown in Fig. 3b , LC3b-I to II conversion was observed starting at 40 lg/ml in MDA-MB 231 cells. No changes in LC3b expression was observed in MCF-7 cells (data not shown). 3-MA is a widely used autophagy inhibitor that inhibits class III phosphoinositide 3-kinase (PI3K). We examined whether 3-MA can inhibit the autophagy induced by Tocomin Ò . As shown in Fig. 3c , co-treatment with 3-MA inhibited the autophagy induced by Tocomin Ò in MDA-MB 231 cells.
Tocomin Ò negatively modulates mTOR pathway
To investigate the mechanisms of Tocomin Ò -induced autophagy, we studied the effects of Tocomin Ò on components of the mTOR pathway including the PI3K class I that regulates mTOR signaling. The PI3K class I is mainly activated via the insulin receptor leading to the activation of AKT and mTOR complex 1 leading to the suppression of autophagy. As shown in Fig. 4 , both p85 and 110a subunits were downregulated after Tocomin Ò treatment. Furthermore, the expression levels of mTOR and Raptor were also downregulated as the concentration of Tocomin Ò was increased.
3-MA modulates Tocomin
Ò -induced apoptosis
Previous studies have shown that during drug-induced protective autophagy, inhibition of the autophagy often leads to enhanced apoptotic response. We reasoned that if, in our case, the autophagy is a resistance mechanism to Tocomin Ò -induced apoptosis, we should also get a similar effect of autophagy inhibition on Tocomin Ò -induced Ò exhibited an increased apoptotic response as evident by PARP cleavage starting very early at 1 h of the combined treatment with profound synergistic apoptotic effect evident at 24 h. The results indicated that 3-MA-mediated inhibition of autophagy modulates Tocomin Ò induced apoptosis.
Discussion
Vitamin E is composed of Ts and T3s that are two structurally similar compounds with diverse physiological functions. Much of the studies on the effects of vitamin E have been performed predominantly on Ts. Recently, several studies have indicated a much prominent role of T3s in human health including their compelling anticancer properties. Studies on purified T3s have shown that in addition to being pro-apoptotic, T3s also inhibit epithelial mesenchymal transition, angiogenesis and exhibit chemosensitizing as well as anticancer stem cell properties [8] . Earlier studies in our laboratory have shown that c-T3-induced apoptosis is dependent on ATF3 and is also associated with UPR leading to ER stress [29] . Autophagy is often activated as a cell survival mechanism followed by ER stress and UPR [31] with its inhibition leading to sensitization to chemotherapeutic drugs [36, [39] [40] [41] . In the present study, we utilized Tocomin Ò as a source of primarily dietary T3s and studied its effects on MDA-MB 231 and MCF-7 breast cancer cells in inducing apoptosis and autophagy. Studies from our laboratory and others performed on purified T3s and TRF from palm oil have demonstrated their apoptotic effects on various cancer cells without affecting non-tumor cells [1, 8, 25, 28, 29] . In a recent study, diet supplementation of T3s to AIN93G-based diet for 13 weeks did not show any side effects in Fisher 344/slc rats [42] . In this study, we did not observe any cell death with Tocomin Ò in non-cancerous MCF-10A cells (Fig. 1) , suggesting a cancer-cell-specific response. Here, we demonstrate that Tocomin Ò inhibits cell proliferation and induces apoptosis in breast cancer cells regardless of their ER and p53 status. ER status independent apoptotic response in breast cancer cells by vitamin E compounds has also been demonstrated in other studies [8, 43, 44] . Next, we studied autophagic response of Tocomin Ò . In triple negative MDA-MB 231 cells, we noticed a profound induction of autophagy as evident by MDC staining and LC3B immunoblotting (Fig. 3) . Interestingly, we did not observe any autophagy in MCF-7 cells when treated with Tocomin Ò . Bioavailability of vitamin E compounds varies for its different isoforms and mode of delivery [45] . Bioavailability of T3s, TRF alone and as inclusion with c-cyclodextrins and other carriers has been studied [45] [46] [47] . Miyoshi et al. [45] reported the Cmax and AUC values in mice receiving TRF have ranged from 7.9 ± 3.3 lM and 47.7 ± 14.6 lM*h, respectively. The concentrations were modestly increased by 1.4 folds when TRF was delivered with c-cyclodextrins (Cmax = 11.5 ± 4.5 lM and AUC = 68.1 ± 18.3 lM*h). The TRF exposure as reported corresponds to the Tocomin Ò concentrations used in this study emphasizing its physiological relevance. Chemopreventive and chemotherapeutic agents (including those that induce ER stress and UPR) are known to induce autophagy in cancer cells, probably, initially as a protective response maintaining cellular homeostasis and eventually as promoter of cell death. In case of ER stress-inducing compounds such as T3s, autophagy can help in cope with ER stress by eliminating the unfolded protein aggregates or ER stressinduced cell death [32, 36, 37] . Although our earlier studies indicated ER stress response in both MCF-7 and MDA-MB 231 cells by purified c-T3 [29] , we did not observe any autophagy in MCF-7 cells that may be explained by difference between the two compounds (Tocomin Ò vs. purified c-T3) or other genetic differences between the two cell lines that are important in regulating autophagy. To eliminate the possibility of batch-specific effect, three independent batches of Tocomin Ò were tested for similar results. To gain insights into the mechanisms involved in inducing autophagy in MDA-MB 231 cells, we analyzed the expression of multiple signaling proteins known to regulate apoptosis and autophagy. Class I PI3K pathway plays important role in the regulation of apoptosis and autophagy. PI3K is activated by growth receptor signaling at the plasma membrane and activates AKT activating mTOR pathway that inhibits autophagy [30, 31, 34] . The PI3K enzyme is composed of a regulatory p85 subunit and a catalytic p110 subunit. P85 binds, stabilizes and inhibits the p110 subunit. As shown in Fig. 4 , we observed downregulation of PI3 kinase subunits and mTOR components in cells treated with Tocomin Ò . Inhibition of PI3K (p85 and p110) along with mTOR and its binding partner Raptor by Tocomin Ò may contribute to its apoptotic and autophagic properties. The interaction of p85 and p110 is a complex process. Inhibition of p85 stabilizes p110 and contributes to cell survival. However, we also observed a downregulation of p110 that suggest an over all negative modulation of PI3K pathway by Tocomin Ò and may be responsible for inhibiting mTOR resulting in apoptosis as well as induction of autophagy. Autophagy induced by anticancer agents can be cytoprotective, and the inhibition of such autophagic response has been shown to enhance cell-death-inducing properties of chemotherapeutic agents [36, 37] . If autophagic response to Tocomin Ò is a cell survival response as it is in case of several anticancer therapies, we asked whether MDA-MB 231 cells can be sensitized to Tocomin Ò by inhibiting autophagy. As shown in Fig. 5 , treatment with a wellknown autophagy inhibitor 3-MA resulted in increased apoptosis in Tocomin Ò -treated cells. 3-MA is a widely used inhibitor of autophagy that blocks the formation of autophagosome by modulating class III PI3K which is involved in the sequestration of cytoplasmic material during autophagy. In conclusion, although further studies are warranted to further elucidate the mechanisms of action of Tocomin Ò , we demonstrate that Tocomin Ò exhibits anticancer effects in breast cancer cells and, like several chemopreventive and chemotherapeutic agents, induces cytoprotective autophagic response.
